National Prostate Cancer Audit: State of the Nation Report 2024
This report shows that Black men have higher rates of stage 3 and stage 4 prostate cancer diagnosis compared to white men, and Black men in their 60s who get a later diagnosis are also less likely to get NICE-approved treatment on the NHS.
A report from a UK clinical consensus on PSA blood testing

Our limited-time only webinar that was recorded at the Guidelines conference in November 2024, about optimising the use of the PSA blood test in asymptomatic men for early prostate cancer detection in primary care. *This recording will expire in November 2025*
PSA consensus recommendations and implications for practice

Dr. Sam Merriel presents PSA consensus recommendations and implications for practice.
Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008–2010
The article reveals that Black men in England face significantly higher lifetime risks of prostate cancer diagnosis and mortality compared to White and Asian men, with the highest diagnosis and death rates among Black men, while mortality rates post-diagnosis are similar across ethnic groups.
Equality, inclusivity, and holistic care of prostate cancer
Siva Tharshini Ramalingam, Cardio-Oncology Specialty Doctor at the Royal Brompton Hospital in London, shares insights on equality, inclusivity, and holistic care of prostate cancer.
Reasonable adjustments for people with Learning Disabilities

Serena Jones, Learning Disability & Autism Acute Liaison Nurse at the Liverpool University Hospitals NHS Foundation Trust, explains which reasonable adjustments to action for patients with learning disabilities when visit them.
Sexual Wellbeing: A Practical Guide

Lorraine Grover, Psychosexual Nurse Specialist at the London Clinic, provides you with a practical guide to support your patients on sexual wellbeing.
The importance of real-world data in prostate cancer

Natalia Norori, Data & Evidence Manager at Prostate Cancer UK, helps us understand the importance of real- world data in prostate cancer.
Considerations for transgender and gender diverse patients with prostate cancer

Stewarts O’Callagham, CEO at OUTpatients, Alison Berner, Academic Clinical Lecturer at the Barts Cancer Institute , and Lloyd Young, patient with lived experience, share their considerations on the LGBTQI+ prostate cancer patients.
Variation in harms and benefits of prostate-specific antigen screening for prostate cancer by socio-clinical risk factors: A rapid review
The article reviews PSA screening for prostate cancer, showing it improves detection of low-grade cancers and reduces advanced cases, especially in men aged 50-55 and those with a family history, but its long-term impact on mortality and ethnic risk needs further research.